Paras Healthcare Limited

Paras Healthcare Limited shows a mixed financial performance with significant recent losses and high operational risks.

Paras Healthcare Limited reported a revenue from operations of ₹16,059.52 million for Fiscal 2026, reflecting a growth from ₹12,940.63 million in Fiscal 2025 and ₹11,290.39 million in Fiscal 2024, indicating a CAGR of 19.26% over the two years. However, the company incurred losses of ₹(579.83) million in Fiscal 2025 and ₹(153.31) million in Fiscal 2024, with a profit of ₹438.34 million in Fiscal 2026. The EBITDA margin improved to 20.60% in Fiscal 2026 from 11.91% in Fiscal 2025, but the company has high attrition rates among healthcare professionals, reported at 60.38% in Fiscal 2026. The debt-equity ratio is projected to improve from 2.16 pre-offer to 1.21 post-offer, with total outstanding fund-based borrowings of ₹8,541.01 million as of March 31, 2026. The company operates six of its eight hospitals on leased premises, which poses additional operational risks. The share count before the offer is 100,986,187, and the fresh issue will dilute existing shareholders by up to 20%. The restated financials cover three fiscal years, providing a basis for trend analysis.

Paras Healthcare Limited operates a network of eight hospitals with a focus on high-acuity specialties, but faces significant operational and financial challenges.

Paras Healthcare Limited, as of March 31, 2026, operates eight hospitals with a total bed capacity of 2,211, primarily in North India, Bihar, and Jharkhand. The company reported revenue from operations of ₹16,059.52 million in Fiscal 2026, with a significant contribution from high-acuity specialties such as cardiac sciences, oncology, and neuro sciences, which collectively accounted for 74.70% of revenue. However, the company has incurred losses in the previous two fiscal years, with a profit of ₹438.34 million in Fiscal 2026 following losses of ₹(579.83) million and ₹(153.31) million in Fiscals 2025 and 2024, respectively. The operational efficiency is further challenged by high attrition rates among healthcare professionals, reported at 60.38% in Fiscal 2026. The company operates six of its eight hospitals on leased premises, which contributed to 60.53% of revenue from operations. The concentration of revenue from North India hospitals is significant, accounting for 66.07% of total revenue in Fiscal 2026. The company plans to expand its capacity to 3,011 beds by March 31, 2028, indicating a commitment to growth despite current challenges.

Paras Healthcare Limited operates a network of eight hospitals in North India, with significant revenue reliance on high-acuity specialties and ongoing regulatory challenges.

Paras Healthcare Limited is positioned within the rapidly growing Indian healthcare delivery market, valued at approximately ₹7.0 trillion in fiscal 2025 and projected to grow at a CAGR of 10% to 12% through fiscal 2030. The company operates eight hospitals across North India, Bihar, and Jharkhand, with a total bed capacity of 2,211 as of March 31, 2026. The company has a strong focus on high-acuity specialties, particularly in cardiac sciences, oncology, neuro sciences, gastro sciences, orthopedics, and renal sciences, which collectively contributed 74.70% of revenue from operations in Fiscal 2026. However, the company faces significant regulatory exposure, including compliance with various healthcare laws and ongoing litigation related to medical negligence and operational practices. The company has reported high attrition rates among healthcare professionals, which could impact service delivery and operational stability. Competitively, Paras Healthcare is one of the largest healthcare providers in its operational regions, but it operates in a challenging environment with significant regulatory scrutiny and financial pressures, including losses reported in recent fiscal years.

Paras Healthcare Limited faces both growth opportunities and significant operational challenges as it prepares for its IPO.

The healthcare delivery market in India is projected to grow at a CAGR of 10% to 12% from fiscal 2025 to 2030, with the North region expected to reach ₹3.6 trillion to ₹3.8 trillion by fiscal 2030. Paras Healthcare Limited, operating eight hospitals with a total bed capacity of 2,211, is positioned to capture this growth, particularly in high-acuity specialties like cardiac sciences and oncology, which contributed 74.70% of its revenue in Fiscal 2026. However, the company has reported significant losses in the past two fiscal years, with ₹(579.83) million in Fiscal 2025 and ₹(153.31) million in Fiscal 2024, primarily due to the ramp-up of new hospitals and high attrition rates among healthcare professionals, which reached 60.38% in Fiscal 2026. The company also faces challenges from regulatory compliance, with ongoing litigations and potential impacts from changes in pricing regulations. Additionally, six of its eight hospitals are operated on leased premises, which could affect operational flexibility and cost structures. While the company has demonstrated revenue growth, the sustainability of profitability remains uncertain, as indicated by the statement, 'We cannot assure you that we will continue to remain profitable in the future.'

Paras Healthcare Limited's IPO reveals a significant reliance on fresh capital for debt reduction and expansion amidst high operational risks.

Paras Healthcare Limited is offering up to ₹18,000 million in its IPO, with a fresh issue of ₹5,000 million aimed at prepaying borrowings and investing in its subsidiary PMHPL. The company currently has total outstanding fund-based borrowings of ₹8,541.01 million, which it expects to reduce to ₹4,791.01 million post-offer, improving its debt-equity ratio from 2.16 to 1.21 times. The company operates eight hospitals with a total bed capacity of 2,211, and plans to expand to 3,011 beds by March 31, 2028. Revenue from operations has shown growth, increasing from ₹11,290.39 million in Fiscal 2024 to ₹16,059.52 million in Fiscal 2026, driven largely by high-acuity specialties that contributed 74.70% of revenue in Fiscal 2026. However, the company has faced significant losses in previous years, with ₹(579.83) million in Fiscal 2025 and ₹(153.31) million in Fiscal 2024. High attrition rates among healthcare professionals, which reached 60.38% in Fiscal 2026, pose a risk to operational stability. The company’s revenue is heavily dependent on its North India hospitals, which accounted for 66.07% of total revenue in Fiscal 2026. The ongoing litigation and regulatory scrutiny further complicate the operational landscape, with outstanding litigation amounting to ₹1,162.25 million.

Paras Healthcare Limited's IPO reveals significant operational challenges and financial instability amidst growth potential.

Paras Healthcare Limited operates eight hospitals with a total bed capacity of 2,211, focusing on high-acuity specialties that contributed 74.70% of its revenue in Fiscal 2026. The company reported a revenue of ₹16,059.52 million in Fiscal 2026, reflecting a CAGR of 19.26% from Fiscal 2024. However, it has incurred losses of ₹(579.83) million and ₹(153.31) million in the previous two fiscal years, raising concerns about its profitability. The company faces high attrition rates among healthcare professionals, averaging 60.38% in Fiscal 2026, which could adversely affect operations. Additionally, six of its eight hospitals are on leased premises, contributing to operational risks. The management acknowledges the potential for future profitability but admits uncertainty regarding maintaining current performance levels. The company has a significant debt burden, with total outstanding fund-based borrowings of ₹8,541.01 million as of March 31, 2026, and plans to reduce this to ₹4,791.01 million post-offer. The IPO is primarily a sale by insiders, with no proceeds going to the company from the offer for sale, raising questions about the timing and pricing of the offering.

Paras Healthcare Limited's IPO reveals significant financial instability and high operational risks.

Paras Healthcare Limited has reported losses in two of the last three fiscal years, specifically ₹(579.83) million in Fiscal 2025 and ₹(153.31) million in Fiscal 2024, indicating a lack of earnings stability. The company only turned a profit of ₹438.34 million in Fiscal 2026, which raises concerns about its ability to maintain profitability. The current ratio and working capital adequacy are not disclosed, leaving uncertainty about liquidity. The debt-to-equity ratio was 3.53 in Fiscal 2026, suggesting high leverage, and the net worth of its subsidiaries is negative, with PHRPL and PMHPL reporting net worths of ₹(1,730.22) million and ₹(893.27) million, respectively. The company has not declared any dividends in the past three fiscal years, which is a red flag for income-seeking investors. Earnings growth is evident with a revenue increase from ₹11,290.39 million in Fiscal 2024 to ₹16,059.52 million in Fiscal 2026, but this is overshadowed by the losses incurred. The filing does not provide a price band, making it impossible to assess the implied valuation against earnings or book value, thus failing the margin of safety test. Overall, the critical failure lies in the lack of consistent profitability and high debt levels, which are significant concerns for a defensive investor.

Paras Healthcare Limited's IPO reveals significant risks amid high promoter shareholding and operational challenges.

The prospectus for Paras Healthcare Limited's IPO indicates a complex landscape for potential investors. The company is offering up to ₹18,000 million, with ₹13,000 million from an offer for sale, primarily by the promoter, Dr. Dharminder Kumar Nagar, who holds 72.80% of the pre-offer equity. This high level of promoter ownership raises questions about the motivations behind the sale, particularly given the company's recent financial struggles, including losses of ₹(579.83) million and ₹(153.31) million in the last two fiscal years. The company has also reported high attrition rates among healthcare professionals, averaging over 60% in recent years, which could impact service quality and operational stability. Furthermore, the concentration of revenue from a few specialties (74.70% from cardiac sciences, oncology, and others) and the reliance on leased premises for six of its eight hospitals (60.53% of revenue) add to the operational risks. The prospectus warns of potential regulatory changes affecting pricing and reimbursement, and the absence of assurances regarding active trading post-listing raises further concerns. The company has also faced outstanding litigations amounting to ₹1,162.25 million, which could adversely affect its reputation and financial condition. Overall, the filing presents a picture of a company with significant operational and financial challenges, raising questions about the sustainability of its business model and the motivations behind the IPO.

Paras Healthcare Limited's IPO reveals significant operational and financial risks amid high attrition and ongoing litigations.

The prospectus for Paras Healthcare Limited's IPO highlights several potential red flags. The company reported losses of ₹(579.83) million and ₹(153.31) million in Fiscals 2025 and 2024, respectively, while generating a profit of ₹438.34 million in Fiscal 2026, raising concerns about earnings sustainability. High attrition rates of 60.38% in Fiscal 2026 could impact operational efficiency and service quality. The company operates six of its eight hospitals on leased premises, which accounted for 60.53% of revenue, indicating a reliance on third-party agreements that could be disrupted. Notably, the prospectus discloses outstanding litigations amounting to ₹1,162.25 million against the company, including allegations of medical negligence and regulatory compliance issues, which could adversely affect its reputation and financial condition. Additionally, the company has significant contingent liabilities of ₹3,905.01 million, raising concerns about its financial stability. Related party transactions accounted for 1.60% of total income, and loans and advances to related parties were 2.55% of total assets, suggesting potential conflicts of interest. The auditor's remarks regarding the audit trail in financial statements further highlight governance concerns. Overall, the prospectus presents a complex picture of operational challenges and financial risks that warrant careful consideration.